Beyond BRCA: new gene panel could sharpen cancer risk prediction

NCT ID NCT03246841

Ongoing Knowledge-focused Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study is investigating whether testing for a panel of 24 genes, in addition to the well-known BRCA1 and BRCA2 genes, can better estimate the risk of breast and ovarian cancer. Researchers will analyze genetic samples from people with a family history of these cancers, as well as their relatives, to see how mutations in these new genes affect cancer risk. The goal is to improve genetic counseling and screening for families at high risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Genetic testing for a panel of 24 genes associated with breast and ovarian cancer susceptibility
What this could lead to: If successful, this could lead to better identification of people at high risk for breast and ovarian cancer, enabling earlier screening and prevention strategies.
What could go wrong: The study is observational and may not directly lead to new treatments. The findings may not apply to all populations, and the clinical utility of the new gene panel is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY BREAST AND OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hereditary breast ovarian cancer syndrome ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY BREAST AND OVARIAN CANCER MUTATION

Contacts and locations

Locations

Gustave Roussy

Paris, France
Institut Curie - PIGE

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.